|
1
|
Chi AC, Day TA and Neville BW: Oral cavity
and oropharyngeal squamous cell carcinoma - an update. CA Cancer J
Clin. 65:401–421. 2015.PubMed/NCBI
|
|
2
|
Li L, Li C, Wang S, Wang Z, Jiang J, Wang
W, Li X, Chen J, Liu K, Li C, et al: Exosomes derived from hypoxic
oral squamous cell carcinoma cells deliver miR-21 to normoxic cells
to elicit a prometastatic phenotype. Cancer Res. 76:1770–1780.
2016.PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI
|
|
4
|
Tseng WT, Chiang WF, Liu SY, Roan J and
Lin CN: The application of data mining techniques to oral cancer
prognosis. J Med Syst. 39:592015.PubMed/NCBI
|
|
5
|
Adami GR, Tang JL and Markiewicz MR:
Improving accuracy of RNA-based diagnosis and prognosis of oral
cancer by using noninvasive methods. Oral Oncol. 69:62–67.
2017.PubMed/NCBI
|
|
6
|
Sharma A, Agarwal K, Agarwal S, Kumar S
and Bharti AC: 354P-Study of immunohistochemical expression of VEGF
and its association with HPV E6 and E7 oncoproteins in oral and
oropharyngeal squamous cell carcinoma. Ann Oncol. 28:100–110.
2017.
|
|
7
|
Smits RW, Koljenović S, Hardillo JA, Ten
Hove I, Meeuwis CA, Sewnaik A, Dronkers EA, Bakker Schut TC,
Langeveld TP, Molenaar J, et al: Resection margins in oral cancer
surgery: Room for improvement. Head Neck. 38:2197–2203. 2016.
|
|
8
|
Zhong LP, Ma H, Ju W and Zhang ZY:
Relationship of low stathmin expression and benefit from TPF
induction chemotherapy and its role in chemoresistance via mutant
p53 in oral cancer. J Clin Oncol. 36:e180342018.
|
|
9
|
Zhong LP, Zhang CP, Ren GX, Guo W, William
WN Jr, Hong CS, Sun J, Zhu HG, Tu WY, Li J, et al: Long-term
results of a randomized phase III trial of TPF induction
chemotherapy followed by surgery and radiation in locally advanced
oral squamous cell carcinoma. Oncotarget. 6:18707–18714.
2015.PubMed/NCBI
|
|
10
|
Shi J, Bao X, Liu Z, Zhang Z, Chen W and
Xu Q: Serum miR-626 and miR-5100 are promising prognosis predictors
for oral squamous cell carcinoma. Theranostics. 9:920–931.
2019.PubMed/NCBI
|
|
11
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005.PubMed/NCBI
|
|
12
|
Kasinski AL, Kelnar K, Stahlhut C,
Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG and Slack
FJ: A combinatorial microRNA therapeutics approach to suppressing
non-small cell lung cancer. Oncogene. 34:3547–3555. 2015.PubMed/NCBI
|
|
13
|
Callegari E, Gramantieri L, Domenicali M,
D'Abundo L, Sabbioni S and Negrini M: MicroRNAs in liver cancer: A
model for investigating pathogenesis and novel therapeutic
approaches. Cell Death Differ. 22:46–57. 2015.PubMed/NCBI
|
|
14
|
Hannafon BN, Trigoso YD, Calloway CL, Zhao
YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ:
Plasma exosome microRNAs are indicative of breast cancer. Breast
Cancer Res. 18:902016.PubMed/NCBI
|
|
15
|
Zeljic K, Jovanovic I, Jovanovic J, Magic
Z, Stankovic A and Supic G: MicroRNA meta-signature of oral cancer:
Evidence from a meta-analysis. Ups J Med Sci. 123:43–49.
2018.PubMed/NCBI
|
|
16
|
Tachibana H, Sho R, Takeda Y, Zhang X,
Yoshida Y, Narimatsu H, Otani K, Ishikawa S, Fukao A, Asao H, et
al: Circulating miR-223 in oral cancer: Its potential as a novel
diagnostic biomarker and therapeutic target. PLoS One.
11:e01596932016.PubMed/NCBI
|
|
17
|
Soga D, Yoshiba S, Shiogama S, Miyazaki H,
Kondo S and Shintani S: microRNA expression profiles in oral
squamous cell carcinoma. Oncol Rep. 30:579–583. 2013.PubMed/NCBI
|
|
18
|
Kukreja P, Parekh D and Roy P: Practical
challenges in measurement of depth of invasion in oral squamous
cell carcinoma: Pictographical documentation to improve consistency
of reporting per the AJCC 8th edition recommendations. Head Neck
Pathol. 2019.doi: 10.1007/s12105-019-01047-9. PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCq method. Methods. 25:402–408. 2001.PubMed/NCBI
|
|
20
|
Necchi A, Lo Vullo S, Perrone F, Raggi D,
Giannatempo P, Calareso G, Nicolai N, Piva L, Biasoni D, Catanzaro
M, et al: First-line therapy with dacomitinib, an orally available
pan-HER tyrosine kinase inhibitor, for locally advanced or
metastatic penile squamous cell carcinoma: Results of an
open-label, single-arm, single-centre, phase 2 study. BJU Int.
121:348–356. 2018.PubMed/NCBI
|
|
21
|
Hosmer DW Jr, Lemeshow S and Sturdivant
RX: Applied Logistic Regression. (3rd). John Wiley & Sons.
(Hoboken, NJ). 173–182. 2013.
|
|
22
|
Yu CC, Hu FW, Yu CH and Chou MY: Targeting
CD133 in the enhancement of chemosensitivity in oral squamous cell
carcinoma-derived side population cancer stem cells. Head Neck.
38:E231–E238. 2016.PubMed/NCBI
|
|
23
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer - a brief overview. Adv Biol Regul. 57:1–9.
2015.PubMed/NCBI
|
|
24
|
Bhattacharya S, Steele R, Shrivastava S,
Chakraborty S, Di Bisceglie AM and Ray RB: Serum miR-30e and
miR-223 as novel noninvasive biomarkers for hepatocellular
carcinoma. Am J Pathol. 186:242–247. 2016.PubMed/NCBI
|
|
25
|
Lu W, Hu Y, Ma Q, Zhou L, Jiang L, Li Z,
Zhao S, Xu Y, Shi W, Li S, et al: miR-223 increases gallbladder
cancer cell sensitivity to docetaxel by downregulating STMN1.
Oncotarget. 7:62364–62376. 2016.PubMed/NCBI
|
|
26
|
Ding Q, Shen L, Nie X, Lu B, Pan X, Su Z,
Yan A, Yan R, Zhou Y, Li L, et al: MiR-223-3p overexpression
inhibits cell proliferation and migration by regulating
inflammation-associated cytokines in glioblastomas. Pathol Res
Pract. 214:1330–1339. 2018.PubMed/NCBI
|
|
27
|
Bozec A, Zangari J, Butori-Pepino M, Ilie
M, Lalvee S, Juhel T, Butori C, Brest P, Hofman P and
Vouret-Craviari V: MiR-223-3p inhibits angiogenesis and promotes
resistance to cetuximab in head and neck squamous cell carcinoma.
Oncotarget. 8:57174–57186. 2017.PubMed/NCBI
|
|
28
|
Zhou X, Jin W, Jia H, Yan J and Zhang G:
MiR-223 promotes the cisplatin resistance of human gastric cancer
cells via regulating cell cycle by targeting FBXW7. J Exp Clin
Cancer Res. 34:282015.PubMed/NCBI
|
|
29
|
Ramos-García P, Bravo M, González-Ruiz L
and González-Moles MÁ: Significance of cytoplasmic cyclin D1
expression in oral oncogenesis. Oral Dis. 24:98–102.
2018.PubMed/NCBI
|
|
30
|
Chen TC, Wu CT, Wang CP, Hsu WL, Yang TL,
Lou PJ, Ko JY and Chang YL: Associations among pretreatment tumor
necrosis and the expression of HIF-1α and PD-L1 in advanced oral
squamous cell carcinoma and the prognostic impact thereof. Oral
Oncol. 51:1004–1010. 2015.PubMed/NCBI
|
